MOLN•benzinga•
Molecular Partners Presents Data From Ongoing Phase 1/2a Trial Of MP0533 In AML At EHA 2025; Three Of Eight Evaluable Patients With R/r AML Responded After Cycle 1 In Ongoing Cohort 8; Data Support Further Dose Optimization To Maximize Therapeutic Benefit
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 11, 2025 by benzinga